MX2019010651A - Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos. - Google Patents

Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos.

Info

Publication number
MX2019010651A
MX2019010651A MX2019010651A MX2019010651A MX2019010651A MX 2019010651 A MX2019010651 A MX 2019010651A MX 2019010651 A MX2019010651 A MX 2019010651A MX 2019010651 A MX2019010651 A MX 2019010651A MX 2019010651 A MX2019010651 A MX 2019010651A
Authority
MX
Mexico
Prior art keywords
delivery device
drug delivery
nauseogenic compound
administration
methods
Prior art date
Application number
MX2019010651A
Other languages
English (en)
Spanish (es)
Inventor
Young Andrew
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intarcia Therapeutics Inc filed Critical Intarcia Therapeutics Inc
Publication of MX2019010651A publication Critical patent/MX2019010651A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019010651A 2017-03-08 2018-03-08 Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos. MX2019010651A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762468399P 2017-03-08 2017-03-08
PCT/US2018/021594 WO2018165462A1 (en) 2017-03-08 2018-03-08 Apparatus and methods for administration of a nauseogenic compound from a drug delivery device

Publications (1)

Publication Number Publication Date
MX2019010651A true MX2019010651A (es) 2020-01-13

Family

ID=61692164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010651A MX2019010651A (es) 2017-03-08 2018-03-08 Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos.

Country Status (10)

Country Link
US (1) US20200188479A1 (https=)
EP (1) EP3592376A1 (https=)
JP (2) JP2020510028A (https=)
KR (1) KR20190126335A (https=)
CN (1) CN110545838A (https=)
AU (1) AU2018231249A1 (https=)
CA (1) CA3055759A1 (https=)
IL (1) IL269001A (https=)
MX (1) MX2019010651A (https=)
WO (1) WO2018165462A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
EP4138780A4 (en) * 2020-04-20 2024-05-15 I2O Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用
US20250268231A1 (en) * 2024-02-27 2025-08-28 Ashop Commerce Pty Ltd. System and method for monitoring and controlling pet activity

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0969016A2 (en) * 1992-06-15 2000-01-05 Scios Inc. Glucagon-like peptide and insulinotropin derivates
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
NZ331186A (en) 1996-02-02 2000-04-28 Alza Corp Osmotically driven sustained delivery drug delivery capsule
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
AU1623099A (en) 1997-12-22 1999-07-12 Alza Corporation Rate controlling membranes for controlled drug delivery devices
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
KR100568917B1 (ko) 1997-12-30 2006-04-07 알자 코포레이션 멤브레인 플러그를 갖는 익제 전달장치
WO1999043706A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
EP1140014B1 (en) 1998-12-31 2003-03-19 Alza Corporation Osmotic delivery system having space efficient piston
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
ES2248156T3 (es) 1999-12-21 2006-03-16 Alza Corporation Valvula para dispositivos osmoticos.
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
DE60317225T2 (de) 2002-06-26 2008-05-29 Intarcia Therapeutics, Inc., Emeryville Minimal nachgiebiger volumen-effizienter kolben für osmotische medikamentenabgabesysteme
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
DE602004012081T2 (de) 2003-03-31 2009-03-19 Intarcia Therapeutics, Inc., Emeryville Osmotische pumpe mit mitteln zum ableiten des innendrucks
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
WO2006081279A2 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
PL1971362T3 (pl) 2005-08-19 2015-05-29 Amylin Pharmaceuticals Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
JP2009534423A (ja) * 2006-04-20 2009-09-24 アムジェン インコーポレイテッド Ｇｌｐ−１化合物
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
WO2008061355A1 (en) * 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
RU2547990C2 (ru) * 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
JP6006118B2 (ja) * 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
CN102946875A (zh) * 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
US20120208755A1 (en) * 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2788027A2 (en) * 2011-12-09 2014-10-15 Novo Nordisk A/S Glp-1 agonists
ES2640285T3 (es) 2012-04-19 2017-11-02 Novo Nordisk A/S Análogos de amilina humana
AU2014261111B2 (en) 2013-05-02 2017-03-16 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
US10479868B2 (en) * 2014-09-04 2019-11-19 Nano Precision Medical, Inc. Polymeric stabilizing formulations
WO2017200944A1 (en) * 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
KR102574993B1 (ko) * 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
JP7286542B2 (ja) * 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法

Also Published As

Publication number Publication date
JP2020510028A (ja) 2020-04-02
JP2023061945A (ja) 2023-05-02
CN110545838A (zh) 2019-12-06
EP3592376A1 (en) 2020-01-15
WO2018165462A1 (en) 2018-09-13
AU2018231249A1 (en) 2019-09-26
CA3055759A1 (en) 2018-09-13
US20200188479A1 (en) 2020-06-18
IL269001A (en) 2019-10-31
KR20190126335A (ko) 2019-11-11

Similar Documents

Publication Publication Date Title
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
HK1248564A1 (zh) 用大麻素的局部区域神经影响性疗法
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
EP4389213A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
MX2019010651A (es) Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos.
WO2015020943A3 (en) Digestive enzyme composition suitable for enteral administration
MX2013012206A (es) Metodo para producir substancias con gas sobresaturado,dispositivo de suministro transdermico de las mismas, y usos de las mismas.
EP4700016A3 (en) Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
MX2020010034A (es) Metodo de tratamiento de enfermedad fibrotica.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
MX2015016750A (es) Composicion inmunogenica para uso en terapia.
MX2017015664A (es) Administracion intravenosa de citrulina durante cirugia.
WO2020243273A3 (en) Methods of treating cholangiocarcinoma
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2013012204A (es) Metodo para producir substancias con gas sobresaturado, dispositivo de suministro transdermico de las mismas, y usos de las mismas.
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
ZA202402868B (en) Treatment method for retinal degeneration
CO2020000529A2 (es) Metodos para tratar hiperinsulinismo congenito
MX2013012205A (es) Metodo para producir substancias con gas sobresaturado, dispositivo de suministro transdermico de las mismas, y usos de las mismas.
RU2015154876A (ru) Способ хирургического лечения диабетического макулярного отека с наличием витреомакулярной тракции
MX2023006765A (es) Metodo para proporcionar terapia de celiprolol a un paciente.